Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741.

View in: PubMed

subject areas

Aged
Antineoplastic Agents, Immunological
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Cetuximab
Female
Humans
Lung Neoplasms
Male
Middle Aged
Proto-Oncogene Proteins B-raf
Registries

authors with profiles

Richard Schilsky